search
Back to results

Time Restricted Eating (TRE) Among Endometrial Cancer Patients (TREND)

Primary Purpose

Endometrial Cancer

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Time Restricted Eating (TRE) Schedule
Sponsored by
University of Utah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Endometrial Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Females aged 18 years or older
  • Diagnosed with endometrial cancer (any stage)
  • Clinically overweight or obese (BMI >= 25 kg/m2)
  • At least 3 months post-cancer surgery and/or treatment
  • Weight stable for 3 months prior to beginning the study (<4kg weight loss/gain)
  • Have a cell phone that is able to download a phone App and able to use phone during the day

Exclusion Criteria:

  • Persons with special dietary requirements
  • Unable to provide informed consent
  • Unable to read, write, or fill in questionnaires in English
  • Insulin dependent diabetes
  • Night shift workers
  • Persons not able to use cell phone during day (like for work)

Sites / Locations

  • Huntsman Cancer InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Time Restricted Eating (TRE) Schedule

Control Schedule

Arm Description

For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.

For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating.

Outcomes

Primary Outcome Measures

Proportion of Women Referred that are Consented
Feasibility of the TRE intervention will be measured be calculating the proportion (%) of women who were referred that were consented into the study. The study will be considered feasible of > 70% of participants are consented and retained.
Attrition as a Function of Time
Number of participants who withdraw throughout the course of the study.
Percent of Scheduled Assessments Completed
Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.
Number of TRE-Adherent Days per Week
Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-16 hours per day during the TRE phase according to the MCC App mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.
Fidelity of Time Restricted Eating (TRE) Intervention
Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%

Secondary Outcome Measures

Change in blood pressure assessed via electronic blood pressure monitor
Blood pressure will be taken using an electronic blood pressure monitor.
Change in waist circumference assessed via measuring tape
Waist circumference will be measured using a measuring tape.
Change in BMI assessed via height and weight
Participants' height and weight will be measured with stadiometer and electronic scales and used to calculate BMI.
Change in fasting blood glucose assessed via blood draw
A small sample of blood will be taken from participants at designated study visits.
Change in HOMA-IR assessed via blood draw
A small sample of blood will be taken from participants at designated study visits.
Change in c-peptide assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Change in triglycerides assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Change in HDL-cholesterol assessed via blood draw
A small sample of blood will be taken from participants at designated study visits
Change in high sensitivity C-reactive protein assessed via blood draw
A small sample of blood will be taken from participants at designated study visits

Full Information

First Posted
February 18, 2021
Last Updated
November 3, 2022
Sponsor
University of Utah
search

1. Study Identification

Unique Protocol Identification Number
NCT04783467
Brief Title
Time Restricted Eating (TRE) Among Endometrial Cancer Patients
Acronym
TREND
Official Title
Feasibility and Acceptability of Time Restricted Eating (TRE) Among Endometrial Cancer Patients: the TREND Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 7, 2021 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Utah

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic health in this population.
Detailed Description
Enrollment: The study team will aim to recruit 15 endometrial cancer patients seen at the Huntsman Cancer Hospital Clinics. Consent may be completed via phone/email or in-person with the study clinical coordinator. Dietary Intervention: Participants who are consented into the study will participate in a 16-week randomized dietary crossover intervention. The dietary intervention includes 5 study visits, and features a baseline visit, 2-week run-in period, 4-week control diet schedule with prepared frozen meals provided to participants, 4-week washout period, and a 6-week, 8 to 10-hour Time Restricted Eating (TRE) protocol (meal provision with 8 to 10-hour eating and 14 to 16-hour fasting periods). Women will be randomized to either control or TRE, then crossover to the other condition. For the control schedule, women will receive frozen lunch and dinner meals and be provided with a standardized breakfast and snacks menu, and there are no restrictions on timing of eating. For the TRE schedule, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. Fasting period will ramp up during the first week (e.g., Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the eating period at the same time each day. Study Visits and Assessments: Women will attend in-person study visits at the Huntsman Cancer Institute Center for Health Outcomes and Population Equity (HOPE). Baseline Visit (Visit 1): The clinical coordinator will obtain consent from the participant. Once consented, women will complete questionnaires to capture information on clinical and demographic factors, and chronotype. Height will be measured using stadiometer, weight will be measured using calibrated scales, waist circumference with measuring tape and blood pressure (BP) using an electronic BP monitor. Participants may take home questionnaires, with mailer, to complete at home. 2-Week Run-In Period: The purpose of the run-in period is to record women's usual times of eating episodes and appetite while following their habitual diet. Appetite will be measured using the MyCircacianClock (mCC) phone app that has the capability to sample subjects' current behaviors and experiences in real time in their natural environment. Women will complete 3 x 24-hour dietary recalls on non-consecutive days (ASA-24) and a physical activity recall (ACT24 available online or phone app, or via telephone conference with the clinical coordinator). Sleep and activity will also be objectively measured for 7-days using an Actiwatch. Visit 2: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured. Control OR TRE Schedules: The participants will be expected to follow their randomized schedule for meal timing. During these schedules, for both study groups, participants will record timing of eating episodes daily using the MyCircadianClock app, complete 3 x 24-hour recalls (ASA24), 1 x ACT24 activity recall, and 7-days of sleep/physical activity will be objectively measured via Actiwatch. Visit 3: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured. 4-Week Washout Period: During the washout period, women can return to their usual lifestyle. Meals will not be provided during this time. Visit 4: Visit 4 will include a telephone call only to discuss the next study phase and schedule meal provision. Visit 5: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured. An exit interview may occur in person or via phone/video conference to ask questions about how well the intervention was tolerated and allow participants to provide feedback. Follow-Up: Approximately 6-months after consent and roughly 10 weeks after the end of the dietary intervention, participants will be asked to complete a follow-up questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Time Restricted Eating (TRE) Schedule
Arm Type
Experimental
Arm Description
For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.
Arm Title
Control Schedule
Arm Type
No Intervention
Arm Description
For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating.
Intervention Type
Behavioral
Intervention Name(s)
Time Restricted Eating (TRE) Schedule
Intervention Description
[See arm/group descriptions]
Primary Outcome Measure Information:
Title
Proportion of Women Referred that are Consented
Description
Feasibility of the TRE intervention will be measured be calculating the proportion (%) of women who were referred that were consented into the study. The study will be considered feasible of > 70% of participants are consented and retained.
Time Frame
From baseline to Visit 5 (Week 16)
Title
Attrition as a Function of Time
Description
Number of participants who withdraw throughout the course of the study.
Time Frame
From baseline to Visit 5 (Week 16)
Title
Percent of Scheduled Assessments Completed
Description
Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.
Time Frame
From baseline to Visit 5 (Week 16)
Title
Number of TRE-Adherent Days per Week
Description
Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-16 hours per day during the TRE phase according to the MCC App mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.
Time Frame
From baseline to Visit 5 (Week 16)
Title
Fidelity of Time Restricted Eating (TRE) Intervention
Description
Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%
Time Frame
From baseline to Visit 5 (Week 16)
Secondary Outcome Measure Information:
Title
Change in blood pressure assessed via electronic blood pressure monitor
Description
Blood pressure will be taken using an electronic blood pressure monitor.
Time Frame
Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in waist circumference assessed via measuring tape
Description
Waist circumference will be measured using a measuring tape.
Time Frame
Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in BMI assessed via height and weight
Description
Participants' height and weight will be measured with stadiometer and electronic scales and used to calculate BMI.
Time Frame
Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in fasting blood glucose assessed via blood draw
Description
A small sample of blood will be taken from participants at designated study visits.
Time Frame
Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in HOMA-IR assessed via blood draw
Description
A small sample of blood will be taken from participants at designated study visits.
Time Frame
Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in c-peptide assessed via blood draw
Description
A small sample of blood will be taken from participants at designated study visits
Time Frame
Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in triglycerides assessed via blood draw
Description
A small sample of blood will be taken from participants at designated study visits
Time Frame
Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in HDL-cholesterol assessed via blood draw
Description
A small sample of blood will be taken from participants at designated study visits
Time Frame
Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Title
Change in high sensitivity C-reactive protein assessed via blood draw
Description
A small sample of blood will be taken from participants at designated study visits
Time Frame
Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Females aged 18 years or older Diagnosed with endometrial cancer (any stage) Clinically overweight or obese (BMI >= 25 kg/m2) At least 3 months post-cancer surgery and/or treatment Weight stable for 3 months prior to beginning the study (<4kg weight loss/gain) Have a cell phone that is able to download a phone App and able to use phone during the day Exclusion Criteria: Persons with special dietary requirements Unable to provide informed consent Unable to read, write, or fill in questionnaires in English Insulin dependent diabetes Night shift workers Persons not able to use cell phone during day (like for work)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mary Playdon, PhD, MPH
Phone
(801) 213-6264
Email
mary.playdon@hci.utah.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mary Playdon, PhD, MPH
Organizational Affiliation
University of Utah
Official's Role
Principal Investigator
Facility Information:
Facility Name
Huntsman Cancer Institute
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mary Playdon, PhD, MPH
Phone
801-213-6264
Email
mary.playdon@hci.utah.edu

12. IPD Sharing Statement

Learn more about this trial

Time Restricted Eating (TRE) Among Endometrial Cancer Patients

We'll reach out to this number within 24 hrs